Azenta's Q4 2024 revenue was $170 million, a 1% decrease year-over-year. However, the combined Sample Management Solutions and Multiomics businesses grew 5% organically. The company reported a diluted EPS from continuing operations of ($0.10) and a non-GAAP diluted EPS of $0.18. They are pursuing the sale of B Medical Systems.
Revenue decreased by 1% year-over-year to $170 million.
Combined Sample Management Solutions and Multiomics businesses grew 5% organically.
Non-GAAP diluted EPS was $0.18, compared to $0.13 in the prior year.
The company announced plans to sell B Medical Systems.
Azenta expects total organic revenue growth in the range of 3% to 5% for fiscal year 2025, excluding B Medical Systems. Adjusted EBITDA margin expansion is expected to be approximately 300 basis points relative to fiscal 2024.
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance